The approval was granted as a class IIb medical device for the treatment of acute and chronic wounds.

It is part of Klox’s patented BioPhotonic platform, which has been developed to heal wounds and address bacterial contamination.

Klox Technologies president and CEO Lise Hébert said: "Klox’s global strategic partnerships in dermatology have enabled us to solidify our position as a leading specialty pharma company.

"With this regulatory approval in hand, we intend to focus our financial and human resources on independently commercializing and realizing the value of our promising wound care franchise as part of a multi-billion dollar global market."

The company intends to launch the product in Europe in 2015.

Klox develops and markets non-invasive BioPhotonic platform, targeting dermatological, wound care and oral health markets.